Delving into the Latest Updates on Mapreg SAS with Synapse

A Double-Blind, Randomized, Controlled Trial of MAP4343 Treatment, a Ligand of the Neurospecific Microtubule Associated Protein-2, for Alcohol Use Disorder

This is a Phase 2, single-site, randomized, double-blind, placebo-controlled, proof-of-concept (POC) study involving 6 weeks of MAP4343 in conjunction with 6 weeks of manual-guided counseling, with 2 follow-up visits at 1 week and 1 month post-treatment.

开始日期2021-12-01

申办/合作机构

The Scripps Research Institute

[+2]

NCT03870776

/ Completed临床2期

Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode

The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.

开始日期2019-06-01

申办/合作机构

Mapreg SAS

[+1]

EUCTR2018-002901-68-FR

/ Completed临床2期

Double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responders patients experiencing a major depressive episode

开始日期2018-10-23

申办/合作机构

Mapreg SAS

100 项与 Mapreg SAS 相关的临床结果

登录后查看更多信息

0 项与 Mapreg SAS 相关的专利（医药）

登录后查看更多信息

1

项与 Mapreg SAS 相关的文献（医药）

2012-03-20·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Correction for Bianchi and Baulieu, 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders

作者: Baulieu, Etienne-Emile ; Bianchi, Massimiliano